此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of a Mobile Menopause Application (EMMA)

2026年9月29日 更新者:Endo Health GmbH

This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.

研究概览

研究类型

介入性

注册 (估计的)

426

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Legal capacity
  • Ability to provide informed consent
  • Residency in Germany
  • Female gender
  • Age ≥18 years
  • Medically confirmed menopausal or other perimenopausal disorder (N95.1)
  • Ownership of a smartphone and ability to use it
  • Internet access for app usage and questionnaire completion
  • Email address for registration
  • Willingness to complete questionnaires online
  • Motivation for regular app usage
  • Sufficient proficiency in the German language
  • MRS II ≥ 9
  • Absence of exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding during the study period
  • Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period
  • Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period
  • Start of psychotherapy within eight weeks prior to study start and/or planned during the study period
  • Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period
  • Surgery performed within eight weeks prior to study start and/or planned during the study period
  • Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
  • Current participation in other clinical studies
  • Failure to meet the inclusion criteria

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
无干预:Control Group

The control group has access to care-as-usual only.

实验性的:Intervention Group

The intervention group has access to the menopause app and its functions in addition to care-as-usual.

The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Menopause-specific quality of life
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL)

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

次要结果测量

结果测量
措施说明
大体时间
Menopause-specific symptom severity
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the Menopause Rating Scale (MRS II)

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Daily interference due to hot flashes
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS)

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Menopause-specific impairment in daily activities
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause)

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Patient activation
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the Patient Activation Measure 13 (PAM-13)

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

其他结果措施

结果测量
措施说明
大体时间
Menopause-specific quality of life
大体时间:Changes between time point T0 (baseline) and T4 (24 weeks after baseline)

Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL)

Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
Menopause-related absenteeism
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the absenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause).

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Menopause-related presenteeism
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the presenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause).

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Menopause-related work productivity loss
大体时间:Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

Assessed with the work productivity loss domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause).

Changes between time point T0 (baseline) and T3 (12 weeks after baseline)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月6日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2026年6月17日

首先提交符合 QC 标准的

2026年6月17日

首次发布 (实际的)

2026年6月23日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • RCT_EMMA

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅